Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1.
A recently discussed cardiovascular risk factor, asymmetric dimethylarginine (ADMA), is known to act as an endogenous inhibitor of endothelial nitric oxide synthase. The aim of this study was to establish 1) the relationship between ADMA and ultrasonographically or biochemically determined endothelial dysfunction in children, and 2) the effect of folate supplementation on these parameters. The study cohort included 32 children with familial hypercholesterolemia (FH), 30 with diabetes mellitus type 1 (DM1) and 30 age-matched healthy children as the control group. Furthermore, twenty-eight randomly selected FH and DM1 children were re-examined after 3-months supplementation with folic acid. Baseline levels of ADMA and oxidized low density lipoproteins (oxLDL) were significantly higher in FH group than in DM1 and healthy children. Children in DM1 group had significantly lower concentration of homocysteine, but ADMA levels were normal. Folic acid supplementation significantly lowered homocysteine and hsCRP levels in both FH and DM1 group; however, ADMA and oxLDL concentrations remained unaltered. In conclusion, ADMA and oxLDL appear to be associated with endothelial dysfunction in children with FH. Administration of folic acid did not influence these markers in both FH and DM1 children.
Jehlicka
P
P
Department of Pediatrics, Charles University in Prague, Plzen, Czech Republic. JEHLICKA@fnplzen.cz
Stožický
F
F
Mayer
O
O
Varvařovská
J
J
Racek
J
J
Trefil
L
L
Siala
K
K
D000293:Adolescent; D000924:Anticholesteremic Agents / Q000008:administration & dosage; D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D001384:Azetidines / Q000008:administration & dosage; D015415:Biomarkers / Q000097:blood; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism*; D004359:Drug Therapy, Combination; D004730:Endothelium, Vascular / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D000069438:Ezetimibe; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D012307:Risk Factors; D014463:Ultrasonography; D014803:Vitamin B Complex / Q000008:administration & dosage*
D000924:Anticholesteremic Agents; D001384:Azetidines; D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein; D014803:Vitamin B Complex; C018524:N,N-dimethylarginine; D005492:Folic Acid; D001120:Arginine; D000069438:Ezetimibe